CY1118138T1 - Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου - Google Patents
Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτουInfo
- Publication number
- CY1118138T1 CY1118138T1 CY20161101076T CY161101076T CY1118138T1 CY 1118138 T1 CY1118138 T1 CY 1118138T1 CY 20161101076 T CY20161101076 T CY 20161101076T CY 161101076 T CY161101076 T CY 161101076T CY 1118138 T1 CY1118138 T1 CY 1118138T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hcmv
- infection
- released
- isomathia
- time
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ένα ιοσωμάτιο το οποίο απελευθερώνεται μετά από μόλυνση κυττάρων θηλαστικών από ανθρώπινο κυτταρομεγαλοϊό (HCMV), όπου a) το σωμάτιο περιβάλλεται από μια λιπιδική μεμβράνη στην οποία ιικές γλυκοπρωτεΐνες είναι ενσωματωμένες, b) το σωμάτιο δεν περιέχει ούτε ιικό DNA ούτε καψίδια˙ και c) το σωμάτιο περιέχει μία πρωτεΐνη σύντηξης η οποία περιλαμβάνει ένα ή περισσότερα μέρη του Τ-κυτταρικού αντιγόνου pp65 και τουλάχιστον ένα ετερόλογο πεπτίδιο, και όπου το τουλάχιστον ένα ετερόλογο πεπτίδιο εισάγεται στην θέση αμινοξέος W175 ή Α534 της αλληλουχίας αμινοξέων του Τ-κυτταρικού αντιγόνου pp65.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003712 | 2010-04-06 | ||
| EP11713689.5A EP2556150B1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
| PCT/EP2011/001712 WO2011124371A1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118138T1 true CY1118138T1 (el) | 2017-06-28 |
Family
ID=43923731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101076T CY1118138T1 (el) | 2010-04-06 | 2016-10-25 | Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9486517B2 (el) |
| EP (1) | EP2556150B1 (el) |
| JP (1) | JP5827312B2 (el) |
| KR (2) | KR20170108167A (el) |
| CN (1) | CN102933706B (el) |
| AU (1) | AU2011238085B2 (el) |
| BR (1) | BR112012025392B1 (el) |
| CA (1) | CA2795346C (el) |
| CY (1) | CY1118138T1 (el) |
| DK (1) | DK2556150T3 (el) |
| ES (1) | ES2601850T3 (el) |
| HR (1) | HRP20161556T1 (el) |
| HU (1) | HUE030704T2 (el) |
| IL (1) | IL222229A (el) |
| LT (1) | LT2556150T (el) |
| MX (1) | MX2012011639A (el) |
| MY (1) | MY162335A (el) |
| PL (1) | PL2556150T3 (el) |
| PT (1) | PT2556150T (el) |
| RS (1) | RS55421B1 (el) |
| RU (1) | RU2623172C2 (el) |
| SG (2) | SG10201502271RA (el) |
| SI (1) | SI2556150T1 (el) |
| SM (1) | SMT201700002B (el) |
| WO (1) | WO2011124371A1 (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| JP7449246B2 (ja) | 2018-06-08 | 2024-03-13 | ワクチン プロジェクト マネジメント ゲーエムベーハー | ウイルス粒子ベースのワクチン |
| EP3587566A1 (en) | 2018-06-29 | 2020-01-01 | Bodo Plachter | Hcmv vaccine strain |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| DE19910044A1 (de) * | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| WO2006004661A1 (en) * | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
-
2011
- 2011-04-06 CN CN201180027797.9A patent/CN102933706B/zh active Active
- 2011-04-06 RS RS20161007A patent/RS55421B1/sr unknown
- 2011-04-06 SG SG10201502271RA patent/SG10201502271RA/en unknown
- 2011-04-06 LT LTEP11713689.5T patent/LT2556150T/lt unknown
- 2011-04-06 MY MYPI2012004446A patent/MY162335A/en unknown
- 2011-04-06 BR BR112012025392-1A patent/BR112012025392B1/pt active IP Right Grant
- 2011-04-06 WO PCT/EP2011/001712 patent/WO2011124371A1/en active Application Filing
- 2011-04-06 HU HUE11713689A patent/HUE030704T2/en unknown
- 2011-04-06 SI SI201131016A patent/SI2556150T1/sl unknown
- 2011-04-06 US US13/639,636 patent/US9486517B2/en active Active
- 2011-04-06 DK DK11713689.5T patent/DK2556150T3/en active
- 2011-04-06 JP JP2013503035A patent/JP5827312B2/ja active Active
- 2011-04-06 CA CA2795346A patent/CA2795346C/en active Active
- 2011-04-06 KR KR1020177025664A patent/KR20170108167A/ko not_active Application Discontinuation
- 2011-04-06 PT PT117136895T patent/PT2556150T/pt unknown
- 2011-04-06 MX MX2012011639A patent/MX2012011639A/es active IP Right Grant
- 2011-04-06 AU AU2011238085A patent/AU2011238085B2/en active Active
- 2011-04-06 ES ES11713689.5T patent/ES2601850T3/es active Active
- 2011-04-06 EP EP11713689.5A patent/EP2556150B1/en active Active
- 2011-04-06 RU RU2012146775A patent/RU2623172C2/ru active
- 2011-04-06 SG SG2012071189A patent/SG184261A1/en unknown
- 2011-04-06 PL PL11713689T patent/PL2556150T3/pl unknown
- 2011-04-06 KR KR1020127028033A patent/KR101839535B1/ko active IP Right Grant
-
2012
- 2012-09-27 IL IL222229A patent/IL222229A/en active IP Right Grant
-
2016
- 2016-10-25 CY CY20161101076T patent/CY1118138T1/el unknown
- 2016-11-22 HR HRP20161556TT patent/HRP20161556T1/hr unknown
-
2017
- 2017-01-02 SM SM201700002T patent/SMT201700002B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118138T1 (el) | Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου | |
| CY1121159T1 (el) | Μη-ενσωματουμενοι λεντiϊικοι φορεις | |
| DK2608806T3 (da) | Epstein-barr-virusvaccine | |
| CY1120489T1 (el) | Εμβολια για hsv-2 | |
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| MX2020010035A (es) | Receptores de celulas t anti-papilomavirus 16 e7 humano. | |
| CL2016003096A1 (es) | Métodos para cosechar cultivos de células de mamífero | |
| CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| CY1106785T1 (el) | Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο | |
| BRPI0922867B8 (pt) | glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada | |
| TR201908199T4 (tr) | HPV'ye karşı aşılar. | |
| EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
| WO2010043650A3 (en) | Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry | |
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| EA201390806A1 (ru) | Конструкция пептидного каркаса | |
| MX358711B (es) | Inmunogenos para vacunacion contra vih. | |
| EA201071086A1 (ru) | Усовершенствованный способ получения вакцинных антигенов вируса гриппа | |
| NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| EA200970731A1 (ru) | Рекомбинантные антигены цитомегаловируса человека (hcmv) | |
| WO2012038832A3 (en) | Generation of replicating chimeric measles virus - retrovirus particles | |
| MX2012002702A (es) | Vacuna de herpesvirus bovino. | |
| EP2632942A4 (en) | RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME | |
| TR201901466T4 (tr) | Opti̇mi̇ze edi̇lmi̇ş feli̇n lösemi̇ vi̇rüsü zarf geni̇ni̇ i̇çeren rekombi̇nant feli̇n lösemi̇ vi̇rüsü |